All Updates

All Updates

icon
Filter
Earnings/results
Small Pharma reports financial and business update for Q3 2023; expands patent portfolio
Psychedelic Medicine
Jan 25, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Jan 25, 2023

Small Pharma reports financial and business update for Q3 2023; expands patent portfolio

Earnings/results

  • In its Q3 financial and business results for the period ended November 30, 2022, UK-based psychedelic company, Small Pharma, reported progress in its clinical development efforts and patent portfolio.

  • The company highlighted a few clinical milestones for the period, including: 1) completing the Phase 2a clinical trial of SPL026, an intravenous (IV) N,N-dimethyltryptamine (DMT) therapy; 2) preparing for a Phase 2b international multi-site clinical trials of SPL026, which it plans to initiate in the 1H of 2023; 3) initiating the drug interaction Phase 1b study of its selective serotonin reuptake inhibitor (SSRI); 4) initiated Phase 1 study in intramuscular administration of SPL026; and 5) collaborated with University College London to provide SPL026 for a neuroplasticity brain-imaging study. 

  • Small Pharma also expanded its patent portfolio with three newly granted patents, bringing the total number of granted patents to 14. It also has over 90 (psychedelic and non-psychedelic) patent applications pending. 

  • Currently, the company has a cash and cash equivalents balance of CAD 22.7 million, compared to CAD 40.7 million in February 2022.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.